Peder L. Myhre MD, PhD
@pmyhre
Followers
1K
Following
7K
Media
224
Statuses
1K
Professor of Cardiology @UniOslo_MED π³π΄ | Director @NorTrials Cardiovascular Center | @Brighamfellows alumni | Circulation On The Run podcast host @CircAHA |
Oslo, Norge
Joined June 2009
I am super excited to share our review article on AI echo in @NatRevCardiol, co-authored by a fantastic group under the leadership of @lamcardio. π https://t.co/bUy4ufB6vn
@bgrenne @FedericoAsch @VDelgadoGarcia @rohan_khera @pattypellikka @ppsengupta1
1
9
54
πΒ ππππ‘π’π§π€π’π§π πππ‘π¨πππ«ππ’π¨π π«ππ©π‘π² π°π’ππ‘ ππ Echocardiography saves lives, but it is also one of the most time-consuming and variable aspects of cardiac care. Variation in measurements, reporting delays, and heavy workloads can all stand between
0
2
2
Fantastic program at the HF Master Course in in Skopje π²π° I had the please to talk about HF biomarkers in a session with @ESC_President, Seferovic, TchΓΆpe ++ The Archbishop and Minister of Health even attended the opening ceremony with the world famous pianist @STrpceski π€©
0
2
11
#CardiogenicShock is Γ₯ feared complications after acute MI, but is the prognosis still poor with modern care? We looked at all MIs in π³π΄ last decade and found in-hosp death: <75y: 48% π >75y: 71% π Good news is that pts surviving to discharge have decent long-term prognosis
3
4
11
All eyes on heart failure in @TheLancet. Three landmark papers led by @mvaduganathan on 1) prevention 2) post-MI 3) CKM π
Wow, HF Prevention Makes Front Page of @TheLancet! Watershed moment to prioritize early screening, diagnosis, & treatment of HF π Identify Stage B βpre-HFβ π» Quantify risk π©Ί Address modifiable RFs π©π½ββοΈ Implement #CKM therapies π«±πΎβπ«²π½ Collaborative care https://t.co/4fqdyVSp86
1
4
24
#EndpointSelection is always a gamble #DIGITHF: recurrent event analyses performed worse than first events (driven by v high drug discontinuation) ..despite double # of events! 1Β°:β οΈ+first π₯ (N=506): 0.82(0.69-0.98) 2Β°:β οΈ+totalπ₯(N=1068): 0.85(0.67-1.09) h/t @Kieranfdocherty
9
13
61
Digital tools in heart failure: addressing unmet needs https://t.co/XQkhteroWB via @pmyhre et al
0
1
1
I was so happy to celebrate @TorBieringβs outstanding presentations & sim pubs at #ESCcongress! Amazing to carve out a career path that is uniquely oneβs own, while pouring in so much effort into mentees. Proud of you, friend. π @CTCPR_
π Most viewed this week from JAMA Cardiology: Among older adults, high-dose influenza vaccine modestly reduced cardiorespiratory and cardiovascular hospitalizations compared to standard-dose vaccine. https://t.co/kh52CuGjuC
0
6
33
Chemotherapy-induced cardiomyopathy (CHIC) is an emerging challenge. Patients with CHIC remain underrepresented in CRT trials. Evidence is limited, highlighting the urgent need for RCTs and a multidisciplinary cardio-oncology approach ( https://t.co/PPJZjP3QRM).
#HREV @pmyhre
link.springer.com
Heart Failure Reviews - Chemotherapy-induced cardiomyopathy (CHIC) represents a growing clinical challenge due to the increasing use of cardiotoxic treatments. These therapies can lead to...
0
3
13
Joining the Circulation family has been one of the highlights of my career What a unique group of smart and kind scientists! Extremely greatful to @josephahill ππ» At #ESCCongress2025 we had a great session showcasing the journal, including #CirculationOnTheRun podcast ππ§
0
2
28
The audience capacity at the small stage Station 3 was truly challenged π
when @JavedButler1 & @FaiezZANNAD presented data on mortality-specific outcomes and HF-specific outcomes from #VICTOR. Honored to co-chair this with @CharlottaLjung4 #ESCCongress2025
0
5
15
Great session by the Circulation editors at #ESC25 β¦@CircAHAβ© β¦@CiccaroneCenterβ© β¦@hopkinsheartβ©
2
13
65
Proud and greatful to share the primary results with this fantastic team (@dan_atar E Prescott AM Kristensen, JE Otterstad) and the Norwegian and Danish cardiac community! Thanks to prof John Cleland for a great discussion. @NEJM @escardio #ESC2025 @VestreViken @atferdsmedisin
Presented at #ESCCongress: Among patients with myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blockers led to a lower risk of death or major cardiovascular events than no beta-blocker therapy. Full BETAMIβDANBLOCK trial results:
2
2
4
π€ Great to meet site reps from across Norway + the steering committee (incl. Justin Ezekowitz) for STRONG@HOME at #ESCCongress. With PI @pmyhre and national lead @Tarjeivrebotten , we are testing if the STRONG-HF strategy can be safely delivered at home with digital follow-up.
0
2
5
βοΈ@Tarjeivrebotten presenting very clinically relevant data on clinical characteristics the prognosis in tachycardia induced #heartfailure
0
1
4
Center leader @OmlandRn presenting the main results from the PRADA II at the ESC Congressπ¨π¦π₯³This multi center RCT tested the effect of ARNI in cancer patients receiving potential cardiotoxic treatment. The primary result was neutral.
0
3
4
Delighted to present these data today at #ESCCongress looking at the potential benefits of the early initiation of disease-modifying therapy in community-based patients with suspected HF Simultaneous publication at @ESC_Journals EHJ https://t.co/1mjvXC3wIZ
10
25
72
π¨ Hot news from #ESCCongress In DIGIT-HF π digitoxin reduced death or first HF hospitalization vs placebo (HR 0.82, p=0.03) in HFrEF (NYHA IIβIV, EF β€40%, on GDMT). β‘οΈ Absolute risk reduction: 4.6% β‘οΈ NNT: 22 #HeartFailure
1
1
1
Very pleased to share our review on AI echocardiography in cardiovascular disease management is now published! I hope this article serves as a resource for continued learning, discussion, and collaboration across the field. π https://t.co/Ue44ZofLpf
13
50
205
New online! Artificial intelligence-enhanced echocardiography in cardiovascular disease management https://t.co/kYBO2C0cSb
1
18
50